Sancuso (Granisetron) Patent Expiration, LOE Window & CMS Spending

Sancuso (Granisetron) by Apotex: Off-Patent Genericized (AB Competition), 4 AB generics, $9.3M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorApotex
FDA Application & PathwayN022198 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors4
2024 CMS Total Public Spend$9.3M
2024 Medicare Part D Spend$6.6M
2024 Medicaid Spend$2.7M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 12.6% 2-yr change)